Why surgery won the SYNTAX trial and why it matters
| Autor: | Bruce W. Lytle, Michael J. Mack, Heike Baumgarten |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty medicine.medical_treatment Myocardial Infarction Coronary Artery Disease Disease 030204 cardiovascular system & hematology Coronary artery disease 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Risk Factors Cause of Death Internal medicine medicine Humans 030212 general & internal medicine Myocardial infarction Coronary Artery Bypass Aged Cause of death business.industry Percutaneous coronary intervention Drug-Eluting Stents Middle Aged medicine.disease humanities Surgery Cardiac surgery medicine.anatomical_structure Conventional PCI Cardiology Female Cardiology and Cardiovascular Medicine business Artery |
| Zdroj: | The Journal of Thoracic and Cardiovascular Surgery. 152:1237-1240 |
| ISSN: | 0022-5223 |
| DOI: | 10.1016/j.jtcvs.2016.04.083 |
| Popis: | The Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial cause of death analysis shows that cardiac death due to myocardial infarction is 10 times higher with percutaneous coronary intervention than coronary artery bypass grafting in the higher-risk patients. There was a clear advantage for surgery in the prevention of death in both the intermediate and high SYNTAX score groups with 3-vessel disease and in the high SYNTAX score group with left main disease, and that incremental advantage is statistically significant and widening with time, which should be transparently communicated to patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|